ORIC ORIC PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ORIC PHARMACEUTICALS INC reported revenue of n/a, net income of −$41.5M and diluted EPS of −$0.38; for the fiscal year ended December 2025 revenue was n/a.
ORIC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$143M, net income −$129M (margin n/a), EPS −$1.47
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$143M, net income −$128M (margin n/a), EPS −$1.83
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$111M, net income −$101M (margin n/a), EPS −$1.96
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$91.8M, net income −$89.1M (margin n/a), EPS −$2.25
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$78.9M, net income −$78.7M (margin n/a), EPS −$2.07
ORIC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$41.5M, EPS −$0.38
- Quarter ended Mar 31, 2026: revenue n/a, net income −$35.8M, EPS −$0.34
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$30.5M, EPS −$0.25
- Quarter ended Sep 30, 2025: revenue n/a, net income −$32.6M, EPS −$0.33
- Quarter ended Jun 30, 2025: revenue n/a, net income −$36.4M, EPS −$0.47
- Quarter ended Mar 31, 2025: revenue n/a, net income −$30.0M, EPS −$0.42
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$36.3M, EPS −$0.52
- Quarter ended Sep 30, 2024: revenue n/a, net income −$34.6M, EPS −$0.49
- Quarter ended Jun 30, 2024: revenue n/a, net income −$32.0M, EPS −$0.45
- Quarter ended Mar 31, 2024: revenue n/a, net income −$25.0M, EPS −$0.37
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$28.3M, EPS −$0.49
- Quarter ended Sep 30, 2023: revenue n/a, net income −$25.5M, EPS −$0.44
- Quarter ended Jun 30, 2023: revenue n/a, net income −$22.9M, EPS −$0.50
- Quarter ended Mar 31, 2023: revenue n/a, net income −$23.9M, EPS −$0.53
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$20.8M, EPS −$0.52
- Quarter ended Sep 30, 2022: revenue n/a, net income −$24.8M, EPS −$0.63
- Quarter ended Jun 30, 2022: revenue n/a, net income −$20.3M, EPS −$0.51
- Quarter ended Mar 31, 2022: revenue n/a, net income −$23.2M, EPS −$0.59
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$22.8M, EPS −$0.58
- Quarter ended Sep 30, 2021: revenue n/a, net income −$18.4M, EPS −$0.47
ORIC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$111M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$113M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$85.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$75.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$59.5M, share buybacks n/a
ORIC balance sheet
- Jun 30, 2026: cash $37.5M, total assets $405M, total liabilities $23.4M, shareholders' equity $381M
- Mar 31, 2026: cash $56.4M, total assets $437M, total liabilities $21.2M, shareholders' equity $416M
- Dec 31, 2025: cash $45.7M, total assets $409M, total liabilities $24.5M, shareholders' equity $384M
- Sep 30, 2025: cash $49.7M, total assets $431M, total liabilities $24.3M, shareholders' equity $407M
- Jun 30, 2025: cash $75.9M, total assets $347M, total liabilities $22.9M, shareholders' equity $324M
- Mar 31, 2025: cash $49.3M, total assets $243M, total liabilities $23.1M, shareholders' equity $220M
- Dec 31, 2024: cash $59.4M, total assets $274M, total liabilities $31.0M, shareholders' equity $243M
- Sep 30, 2024: cash $44.2M, total assets $302M, total liabilities $28.1M, shareholders' equity $274M
Is ORIC profitable?
No. ORIC PHARMACEUTICALS INC lost $140M over the last four quarters.
What is ORIC's EPS?
Diluted earnings per share over the last four quarters were −$1.30; −$0.38 in the latest quarter.